To provide a rigorous **Results** section for your publication, I have drafted the text based on your LMM findings. This draft follows standard reporting guidelines (like STROBE or CONSORT) for longitudinal clinical data.

---

## Results

### 3.1 Patient Characteristics and Data Completeness

A total of 50 patients were enrolled in the study. The longitudinal dataset comprised a total of 182 observations (Run 1) and 177 observations (Run 2) across four timepoints (Baseline, 3, 6, and 12 months). The mean number of observations per patient was 3.6 (SD 0.4), reflecting a low attrition rate. Missing data at the 12-month mark (24% maximum simulated attrition) was handled via Restricted Maximum Likelihood (REML) estimation within the Linear Mixed Model framework, allowing for the inclusion of all patients in the final analysis.

### 3.2 Clinical Severity (CEAP) and Baseline QoL

Baseline VEINES-QOL scores showed a strong, inverse relationship with the CEAP clinical classification. In the primary model (Run 1), patients with CEAP C6 (active ulcer) exhibited the most severe reduction in quality of life, with a mean score  points lower than the C1 reference group (). A "stepladder" degradation was observed across all classes, with C4 () and C5 () showing significantly lower scores compared to uncomplicated disease. While CEAP C2 was significant in Run 1 (), it did not reach significance in the second cohort (), suggesting variability in QoL impact for minor varicose veins.

### 3.3 Longitudinal QoL Recovery

Significant improvements in VEINES-QOL were observed over the 12-month follow-up period. Using the categorical visit model, QoL gains were statistically detectable as early as 3 months () compared to baseline (Run 1:  pts, ; Run 2:  pts, ). The most substantial recovery was realized at the 12-month visit, with a mean improvement of  points in Run 1 and  points in Run 2 ( for both).

### 3.4 Influence of Body Mass Index (BMI)

BMI was identified as a stable and significant independent predictor of diminished QoL. For every 1-unit increase in BMI, VEINES-QOL scores decreased by  points in Run 1 () and  points in Run 2 (). This negative association persisted even when controlling for CEAP clinical stage and time.

### 3.5 Model Variance and Subject Heterogeneity

The Linear Mixed Model revealed substantial subject-level heterogeneity, with a Group Variance of  (Run 1) and  (Run 2). The high ratio of Group Variance to Residual Scale ( and , respectively) confirms that individual patient factors accounted for a significant portion of the total variance, validating the use of random intercepts over standard linear regression.

---

### Summary Table for Publication

| Variable | Coefficient () | Std. Error | -value | -value |
| --- | --- | --- | --- | --- |
| **Intercept (C1 Baseline)** | 50.08 | 5.30 | 9.46 | < 0.001 |
| **Visit: 12 Months** | +6.47 | 0.51 | 12.60 | < 0.001 |
| **CEAP: C4** | -14.52 | 2.69 | -5.40 | < 0.001 |
| **CEAP: C6** | -24.74 | 2.60 | -9.52 | < 0.001 |
| **BMI** | -0.38 | 0.18 | -2.17 | 0.030 |

---

**Would you like me to help you draft the Discussion section, specifically focusing on how these findings compare to existing literature regarding the "C" variable in CEAP?**